Capital RaisingSince 2014, Sen-Jam has been on a mission to revolutionize pain management - driven to usher in a new dawn for humanity around full strength living
Sen-Jam has been working hard amassing 25 both domestic and international patents and patents pending
-
August
-
May
Intellectual Property Update
Australian Patent Granted AU2016235484B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
May
Intellectual Patent Update
Japan Patent Granted JP6851365B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
April
Intellectual Patent Update
South Africa Patent Granted 201706794B for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
March
COVID-19 Research Paper Published
-
February
Licensing Update
Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-002C (COVID-19 Treatment) for Colombia with expansion rights to Central and South America.
-
February
Intellectual Patent Update
Received Notice of Patent Allowance from the Japanese Intellectual Patent Office for SJP-001 (Alcohol Hangover Prevention)
Received Notice of Acceptance from the Australian Patent Office for SJP-001 (Alcohol Hangover Prevention)
-
February
Opioid Withdrawal Research Papers Published
Functional observation after morphine withdrawal: effects of SJP-005
A Comparison of the Antinociceptive Properties of SJP-005 and Morphine in Rats
2021
-
December
Intellectual Property Update
US Patent Award No. 10,874,653 for Methods and Compositions to Inhibit Adverse Effects of Vaccinations (SJP-003)
-
October
Licensing Update
Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-001 (Hangover Prevention) for Colombia with expansion rights to Central and South America.
-
September
Intellectual Property Update
US Patent Award No. 10,765,630 for Methods and Compositions to Treat Enteropathic Arthritis (SJP-004)
-
June
Completed Mentorship program for 2 Northeastern Capstone groups
Sen-Jam wins Life Science Nation Digital RESI Innovation Challenge
-
June
Intellectual Property Update
US Patent Award No. 10,675,261 for Methods and Compositions to Inhibit Dependence of Opioids (SJP-006)
-
May
Selected as Finalist for Life Science Nation Digital RESI Innovation Challenge
Selected as Featured Company for Life Science Nation Digital RESI COVID-19 Solution Presentation
Selected to Present COVID-19 Solution at Biotechnology Innovation Organization (BIO) Digital Conference
Entered Collaborative Partnership Agreement with Assistance Publique - Hopitaux De Paris to Study Treatments for COVID-19
Featured in COVID-19: Treatments before Vaccines Webinar with AdvancedDx Biological Laboratories
-
April
In-Vitro Study underway testing SJP-002 against the COVID-19 virus
Listed on RedCrow’s Equity CrowdFunding site
Sen-Jam featured in StartUp Healths Insights
-
March
Alcohol Hangover Paper Published featuring SJP-001
-
March
Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone
-
January
Sen-Jam participates in StartUp Health Festival during JP Morgan Health Conference2020
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
November
Presented at Life Science Summit, NYC
-
Fall
Patent issued for SJP-001
-
September
Led panel discussion for Opioid Crisis Working Group -
August
Highlighted in Real Leaders Magazine for work related to opioid withdrawal -
July
Op Ed published in StartUp Health Magazine
-
June
Partnered with Stony Brook University - Center for Biotechnology
-
Spring
Conducted additional pre-clinical studies for opioid withdrawal (SJP-005)
-
January
Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference
2019
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
June
Sen-Jam attends Research Society on Alcoholism Conference
-
May
Sen-Jam attends BioTech event at Cold Spring Harbor Labs
-
Spring
Spring pre-clinical studies for opioid withdrawal (SJP-005)
-
March
Sen-Jam files patent for treatment of enteropathic arthritis (SJP-004)
-
January
Sen-Jam attends JP Morgan Health Conference
2018
-
November
Sen-Jam Wins RESI Innovation Challenge
-
October
Sen-Jam first Corporate Retreat
-
September
Sen-Jam files patents to inhibit symptoms associated with opioid withdrawal (SJP-005), opioid dependence (SJP-006), and opioid tolerance (SJP-007)
-
August
Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)
-
August
Sen-Jam Pharmaceutical LLC is formed
-
July
Sen-Jam attends Research Society on Alcoholism Conference
-
June
Investigational New Drug (IND) application opened with the FDA to begin Phase I Clinical Trial
-
June
Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)
-
April
Sen-Jam presents in Amsterdam at 9th annual Alcohol Hangover Research Group Conference
2017
-
October
Sen-Jam completes Pre-Investigational new drug meeting with FDA
-
August
Trademarks filed & Scientific Advisory Board established
-
June
Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference
-
March
Conducted IRB Study for Prevention of Alcohol Hangover (SJP-001)
2016
-
March
Provisional Patents Filed
2015
-
Fall
Volunteer Study Begins—SJP-001
-
Spring
Jackie Iversen has Eureka moment
2014